title: Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials.
abstract: BACKGROUND
  The National Epirubicin Adjuvant Trial (NEAT) and BR9601 trials tested the benefit of epirubicin when added to cyclophosphamide, methotrexate and 5-fluorouracil (E-CMF) compared with standard CMF in adjuvant chemotherapy for women with early breast cancer. This report details longer follow-up with interesting additional time-dependent analyses.
  
  
  METHODS
  National Epirubicin Adjuvant Trial used epirubicin (E) 3-weekly for four cycles followed by classical (c) CMF for four cycles (E-CMF) compared with cCMF for six cycles. BR9601 used E 3-weekly for four cycles followed by CMF 3-weekly for four cycles, compared with CMF 3-weekly for eight cycles.
  
  
  RESULTS
  In all, 2391 eligible patients were randomised and with a median 7.4-year follow-up, E-CMF confirmed a significant benefit over CMF in both relapse-free survival (RFS) (78% vs 71% 5 years RFS, respectively, hazard ratio (HR)=0.75 (95% CI: 0.65-0.86), P<0.0001) and overall survival (OS) (84% vs 78% 5 years OS, respectively, HR=0.76 (95% CI: 0.65-0.89), P=0.0007). Interaction of treatment effect and prognostic factors was demonstrated for duplication of chromosome 17 centromeric enumeration (Ch17CEP) as previously reported. Poor prognostic factors at diagnosis (ER and PR negative and HER2 positive) showed time-dependent annual hazard rates for RFS and OS. In univariate analysis, these factors demonstrated more favourable HRs for RFS after 5 years. Treatment effects also suggested a differential benefit for E-CMF within the first 5 years for poor prognosis tumours.
  
  
  CONCLUSIONS
  Longer follow-up has confirmed E-CMF as significantly superior to CMF for all patients. Ch17CEP duplication was the only biomarker that demonstrated significant treatment interaction. Standard poor prognostic factors at diagnosis were time-dependent, and after 5 years disease-free, poor prognosis patients demonstrated favourable HRs for survival.
authors.affiliation: Department of Oncology, University of Cambridge, Addenbrooke's Hospital, UK. hme22@cam.ac.uk
authors.forename: H M
authors.initials: HM
authors.lastname: Earl
authors.forename: L
authors.initials: L
authors.lastname: Hiller
authors.forename: J A
authors.initials: JA
authors.lastname: Dunn
authors.forename: A-L
authors.initials: AL
authors.lastname: Vallier
authors.forename: S J
authors.initials: SJ
authors.lastname: Bowden
authors.forename: S D
authors.initials: SD
authors.lastname: Jordan
authors.forename: F
authors.initials: F
authors.lastname: Blows
authors.forename: A
authors.initials: A
authors.lastname: Munro
authors.forename: S
authors.initials: S
authors.lastname: Bathers
authors.forename: R
authors.initials: R
authors.lastname: Grieve
authors.forename: D A
authors.initials: DA
authors.lastname: Spooner
authors.forename: R
authors.initials: R
authors.lastname: Agrawal
authors.forename: I
authors.initials: I
authors.lastname: Fernando
authors.forename: A M
authors.initials: AM
authors.lastname: Brunt
authors.forename: S M
authors.initials: SM
authors.lastname: O'Reilly
authors.forename: S M
authors.initials: SM
authors.lastname: Crawford
authors.forename: D W
authors.initials: DW
authors.lastname: Rea
authors.forename: P
authors.initials: P
authors.lastname: Simmonds
authors.forename: J L
authors.initials: JL
authors.lastname: Mansi
authors.forename: A
authors.initials: A
authors.lastname: Stanley
authors.forename: K
authors.initials: K
authors.lastname: McAdam
authors.forename: L
authors.initials: L
authors.lastname: Foster
authors.forename: R C F
authors.initials: RC
authors.lastname: Leonard
authors.forename: C J
authors.initials: CJ
authors.lastname: Twelves
authors.forename: D
authors.initials: D
authors.lastname: Cameron
authors.forename: J M S
authors.initials: JM
authors.lastname: Bartlett
authors.forename: P
authors.initials: P
authors.lastname: Pharoah
authors.forename: E
authors.initials: E
authors.lastname: Provenzano
authors.forename: C
authors.initials: C
authors.lastname: Caldas
authors.forename: C J
authors.initials: CJ
authors.lastname: Poole
mesh_terms: D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D055118:Medication Adherence; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged
chemical_list: D000903:Antibiotics, Antineoplastic; D015251:Epirubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate